Risk of fracture incidence in prostate cancer survivors: a nationwide cohort study in South Korea

Arch Osteoporos. 2020 Jul 22;15(1):110. doi: 10.1007/s11657-020-00785-6.

Abstract

Purpose: We analyzed the risk of fracture in prostate cancer (PC) survivors compared to that in the general population in South Korea and according to the primary treatment.

Methods: From 2007 to 2013, a total of 41,733 PC survivors newly diagnosed with PC in South Korea were identified and matched to non-cancer controls. Cox proportional hazards regression analysis was performed to determine the relative risk of fracture.

Results: Compared to the matched controls, PC survivors had a higher risk of fracture (adjusted hazard ratio (aHR) 1.39; 95% confidence interval (CI) 1.33-1.45). Compared to the matched controls, the active surveillance/watchful waiting and radiotherapy group showed a similar risk of fracture (aHR 1.08; 95% CI 0.98-1.20, and aHR 1.04; 95% CI 0.63-1.73, respectively). PC survivors who underwent surgery showed a lower risk of fracture (aHR 0.89; 95% CI 0.82-0.96), while those who underwent surgery + androgen deprivation therapy (ADT) (aHR 1.41; 95% CI 1.26-1.57), radiotherapy + ADT (aHR 1.86; 95% CI 1.50-2.32), and only ADT (aHR 1.92; 95% CI 1.82-2.02) showed a higher risk of fracture than the control group.

Conclusion: The risk of fracture differed according to the primary treatment method for PC; survivors who underwent surgery had a lower risk of fracture compared to that of the general population. However, PC survivors treated with ADT showed a higher risk of fracture than the other PC treatment groups or the general population. Therefore, more attention and preventive bone care are required for PC survivors who receive ADT.

Keywords: Androgen deprivation therapy; Fracture; Population-based national wide study; Prostate cancer.

MeSH terms

  • Androgen Antagonists
  • Cancer Survivors*
  • Cohort Studies
  • Humans
  • Incidence
  • Male
  • Proportional Hazards Models
  • Prostatic Neoplasms* / epidemiology
  • Prostatic Neoplasms* / therapy
  • Republic of Korea / epidemiology
  • Survivors

Substances

  • Androgen Antagonists